Detection of clonal and subclonal copy-number variants in cell-free DNA from patients with breast cancer using a massively multiplexed PCR methodology

Translational Oncology

Volumn 8, Issue 5, 2015, Pages 407-416

  Kirkizlar, Eser ^a   Zimmermann, Bernhard ^a   Constantin, Tudor ^a   Swenerton, Ryan ^a   Hoang, Bin ^a   Wayham, Nicholas ^a   Babiarz, Joshua E ^a   Demko, Zachary ^a   Pelham, Robert J ^a   Kareht, Stephanie ^a   Simon, Alexander L ^a   Jinnett, Kristine N ^a   Rabinowitz, Matthew ^a   Sigurjonsson, Styrmir ^a   Hill, Matthew ^a  

^a NATERA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL FREE DNA; DNA; DNA FRAGMENT; GENOMIC DNA; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELIC IMBALANCES; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CLONAL COPY NUMBER VARIATION; CONTROLLED STUDY; COPY NUMBER VARIATION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; NEXT GENERATION SEQUENCING; SUBCLONAL COPY NUMBER VARIATION;

EID: 84945925969     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2015.08.004     Document Type: Article

References (49)

1. Meacham CE and Morrison SJ (2013). Tumour heterogeneity and cancer cell plasticity. Nature 501, 328–337. http://dx.doi.org/10.1038/nature12624
2. Swanton C (2012). Intratumor heterogeneity: evolution through space and time. Cancer Res 72, 4875–4882. http://dx.doi.org/10.1158/0008-5472.can-12-2217
3. Gerlinger M, McGranahan N, Dewhurst SM, Burrell RA, Tomlinson I, and Swanton C (2014). Cancer: evolution within a lifetime. Annu Rev Genet 48, 215–236. http://dx.doi.org/10.1146/annurev-genet-120213-092314
4. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz Jr LA, and Kinzler KW (2013). Cancer genome landscapes. Science 339, 1546–1558. http://dx.doi.org/10.1126/science.1235122
5. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, and Sander C (2013). Emerging landscape of oncogenic signatures across human cancers. Nat Genet 45, 1127–1133. http://dx.doi.org/10.1038/ng.2762
6. Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, Tabak B, Lawrence MS, Zhang CZ, Wala J, and Mermel CH, et al (2013). Pan-cancer patterns of somatic copy number alteration. Nat Genet 45, 1134–1140. http://dx.doi.org/10.1038/ng.2760
7. Kim TM, Xi R, Luquette LJ, Park RW, Johnson MD, and Park PJ (2013). Functional genomic analysis of chromosomal aberrations in a compendium of 8000 cancer genomes. Genome Res 23, 217–227. http://dx.doi.org/10.1101/gr.140301.112
8. The Cancer Genome Atlas Network (2012). Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337. http://dx.doi.org/10.1038/nature11252
9. The Cancer Genome Atlas Network (2012). Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70. http://dx.doi.org/10.1038/nature11412
10. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, and Bignell GR, et al (2012). The landscape of cancer genes and mutational processes in breast cancer. Nature 486, 400–404. http://dx.doi.org/10.1038/nature11017
11. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, and Urashima M, et al (2010). The landscape of somatic copy-number alteration across human cancers. Nature 463, 899–905. http://dx.doi.org/10.1038/nature08822
12. Stratton MR, Campbell PJ, and Futreal PA (2009). The cancer genome. Nature 458, 719–724. http://dx.doi.org/10.1038/nature07943
13. Russnes HG, Navin N, Hicks J, and Borresen-Dale AL (2011). Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest 121, 3810–3818. http://dx.doi.org/10.1172/JCI57088
14. Fisher R, Pusztai L, and Swanton C (2013). Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 108, 479–485. http://dx.doi.org/10.1038/bjc.2012.581
15. Jamal-Hanjani M, Quezada SA, Larkin J, and Swanton C (2015). Translational implications of tumor heterogeneity. Clin Cancer Res 21, 1258–1266. http://dx.doi.org/10.1158/1078-0432.CCR-14-1429
16. Seoane J and De Mattos-Arruda L (2014). The challenge of intratumour heterogeneity in precision medicine. J Intern Med 276, 41–51. http://dx.doi.org/10.1111/joim.12240
17. Burrell RA, McGranahan N, Bartek J, and Swanton C (2013). The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501, 338–345. http://dx.doi.org/10.1038/nature12625
18. Barber LJ, Davies MN, and Gerlinger M (2014). Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale. Curr Opin Genet Dev 30C, 1–6. http://dx.doi.org/10.1016/j.gde.2014.12.001
19. Bedard PL, Hansen AR, Ratain MJ, and Siu LL (2013). Tumour heterogeneity in the clinic. Nature 501, 355–364. http://dx.doi.org/10.1038/nature12627
20. Diaz Jr LA and Bardelli A (2014). Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 32, 579–586. http://dx.doi.org/10.1200/JCO.2012.45.2011
21. DeMattos-Arruda L, Cortes J, Santarpia L, Vivancos A, Tabernero J, Reis-Filho JS, and Seoane J (2013). Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol 10, 377–389. http://dx.doi.org/10.1038/nrclinonc.2013.80
22. Bidard FC, Weigelt B, and Reis-Filho JS (2013). Going with the flow: from circulating tumor cells to DNA. Sci Transl Med 5, 207ps214. http://dx.doi.org/10.1126/scitranslmed.3006305
23. Lebofsky R, Decraene C, Bernard V, Kamal M, Blin A, Leroy Q, Rio Frio T, Pierron G, Callens C, and Bieche I, et al (2015). Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Mol Oncol 9, 783–790. http://dx.doi.org/10.1016/j.molonc.2014.12.003
24. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, and Alani RM, et al (2014). Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6, 224ra224. http://dx.doi.org/10.1126/scitranslmed.3007094
25. Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, Liu CL, Neal JW, Wakelee HA, and Merritt RE, et al (2014). An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 20, 548–554. http://dx.doi.org/10.1038/nm.3519
26. Chan KC, Jiang P, Zheng YW, Liao GJ, Sun H, Wong J, Siu SS, Chan WC, Chan SL, and Chan AT, et al (2013). Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem 59, 211–224. http://dx.doi.org/10.1373/clinchem.2012.196014
27. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, and Mahler-Araujo B, et al (2013). Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368, 1199–1209. http://dx.doi.org/10.1056/NEJMoa1213261
28. Heitzer E, Ulz P, Belic J, Gutschi S, Quehenberger F, Fischereder K, Benezeder T, Auer M, Pischler C, and Mannweiler S, et al (2013). Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med 5, 30. http://dx.doi.org/10.1186/gm434
29. Kukita Y, Uchida J, Oba S, Nishino K, Kumagai T, Taniguchi K, Okuyama T, Imamura F, and Kato K, et al (2013). Quantitative identification of mutant alleles derived from lung cancer in plasma cell-free DNA via anomaly detection using deep sequencing data. PLoS One 8 e81468. http://dx.doi.org/10.1371/journal.pone.0081468
30. Shaw JA, Page K, Blighe K, Hava N, Guttery D, Ward B, Brown J, Ruangpratheep C, Stebbing J, and Payne R, et al (2012). Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. Genome Res 22, 220–231. http://dx.doi.org/10.1101/gr.123497.111
31. Narayan A, Carriero NJ, Gettinger SN, Kluytenaar J, Kozak KR, Yock TI, Muscato NE, Ugarelli P, Decker RH, and Patel AA, et al (2012). Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using errorsuppressed multiplexed deep sequencing. Cancer Res 72, 3492–3498. http://dx.doi.org/10.1158/0008-5472.can-11-4037
32. DeMattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CK, Nuciforo P, Bidard FC, Aura C, Saura C, and Peg V, et al (2014). Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumorDNA: a proof-of-principle. Ann Oncol 25, 1729–1735. http://dx.doi.org/10.1093/annonc/mdu239
33. Heidary M, Auer M, Ulz P, Heitzer E, Petru E, Gasch C, Riethdorf S, Mauermann O, Lafer I, and Pristauz G, et al (2014). The dynamic range of circulating tumor DNA in metastatic breast cancer. Breast Cancer Res 16, 421. http://dx.doi.org/10.1186/s13058-014-0421-y.
34. Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, O'Shaughnessy J, Kinzler KW, Parmigiani G, and Vogelstein B, et al (2012). Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 4, 162ra154. http://dx.doi.org/10.1126/scitranslmed.3004742
35. Pergament E, Cuckle H, Zimmermann B, Banjevic M, Sigurjonsson S, Ryan A, Hall MP, Dodd M, Lacroute P, and Stosic M, et al (2014). Single-nucleotide polymorphism-based noninvasive prenatal screening in a high-risk and low-risk cohort. Obstet Gynecol 124, 210–218. http://dx.doi.org/10.1097/AOG.0000000000000363
36. Samango-Sprouse C, Banjevic M, Ryan A, Sigurjonsson S, Zimmermann B, Hill M, Hall MP, Westemeyer M, Saucier J, and Demko Z, et al (2013). SNP-based non-invasive prenatal testing detects sex chromosome aneuploidies with high accuracy. Prenat Diagn 33, 643–649. http://dx.doi.org/10.1002/pd.4159
37. Wapner RJ, Babiarz JE, Levy B, Stosic M, Zimmermann B, Sigurjonsson S, Wayham N, Ryan A, Banjevic M, and Lacroute P, et al (2015). Expanding the scope of noninvasive prenatal testing: detection of fetal microdeletion syndromes. Am J Obstet Gynecol 212(332), e331–e339. http://dx.doi.org/10.1016/j.ajog.2014.11.041
38. Zimmermann B, Hill M, Gemelos G, Demko Z, Banjevic M, Baner J, Ryan A, Sigurjonsson S, Chopra N, and Dodd M, et al (2012). Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic loci. Prenat Diagn 32, 1233–1241. http://dx.doi.org/10.1002/pd.3993
39. Nicolaides KH, Syngelaki A, Gil M, Atanasova V, and Markova D (2013). Validation of targeted sequencing of single-nucleotide polymorphisms for non-invasive prenatal detection of aneuploidy of chromosomes 13, 18, 21, X, and Y. Prenat Diagn 33, 575–579. http://dx.doi.org/10.1002/pd.4103
40. Untergasser A, Nijveen H, Rao X, Bisseling T, Geurts R, and Leunissen JA (2007). Primer3Plus, an enhanced web interface to Primer3. Nucleic Acids Res 35, W71–W74. http://dx.doi.org/10.1093/nar/gkm306.
41. Li H and Durbin R (2009). Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760. http://dx.doi.org/10.1093/bioinformatics/btp324
42. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, and Genome Project Data Processing Subgroup (2009). The sequence alignment/map format and SAMtools. Bioinformatics 25, 2078–2079. http://dx.doi.org/10.1093/bioinformatics/btp352
43. Levy B, Sigurjonsson S, Pettersen B, Maisenbacher MK, Hall MP, Demko Z, Lathi RB, Tao R, Aggarwal V, and Rabinowitz M (2014). Genomic imbalance in products of conception: single-nucleotide polymorphism chromosomal microarray analysis. Obstet Gynecol 124, 202–209. http://dx.doi.org/10.1097/AOG.0000000000000325
44. Martinez P, McGranahan N, Birkbak NJ, Gerlinger M, and Swanton C (2013). Computational optimisation of targeted DNA sequencing for cancer detection. Sci Rep 3. http://dx.doi.org/10.1038/srep03309
45. Perkins G, Yap TA, Pope L, Cassidy AM, Dukes JP, Riisnaes R, Massard C, Cassier PA, Miranda S, and Clark J, et al (2012). Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One 7 e47020. http://dx.doi.org/10.1371/journal.pone.0047020
46. Bashashati A, Ha G, Tone A, Ding J, Prentice LM, Roth A, Rosner J, Shumansky K, Kalloger S, and Senz J, et al (2013). Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol 231, 21–34. http://dx.doi.org/10.1002/path.4230
47. Snyder M, Adey A, Kitzman JO, and Shendure J (2015). Haplotype-resolved genome sequencing: experimental methods and applications. Nat Rev Genet 16, 344–358. http://dx.doi.org/10.1038/nrg3903
48. Kaper F, Swamy S, Klotzle B, Munchel S, Cottrell J, Bibikova M, Chuang HY, Kruglyak S, Ronaghi M, and Eberle MA, et al (2013). Whole-genome haplotyping by dilution, amplification, and sequencing. Proc Natl Acad Sci U S A 110, 5552–5557. http://dx.doi.org/10.1073/pnas.1218696110
49. Kuleshov V, Xie D, Chen R, Pushkarev D, Ma Z, Blauwkamp T, Kertesz M, and Synder M, et al (2014).Whole-genome haplotyping using long reads and statistical methods. Nat Biotechnol 32, 261–266. http://dx.doi.org/10.1038/nbt.2833.